Delving into the Latest Updates on Astellas Pharma Technologies, Inc. with Synapse

概览

排名前五的药物类型	数量

小分子化药	1

排名前五的靶点	数量

M3 receptor x β3-adrenergic receptor	1

关联

1

项与 Astellas Pharma Technologies, Inc. 相关的药物

Mirabegron/Solifenacin Succinate

米拉贝隆/琥珀酸索利那新

靶点

M3 receptor x β3-adrenergic receptor

作用机制

M3 receptor拮抗剂 [+1]

在研机构

Astellas Pharma Technologies, Inc. [+1]

原研机构

Astellas Pharma, Inc.

在研适应症

膀胱过度活动症

非在研适应症-

最高研发阶段临床3期

首次获批国家/地区-

首次获批日期-

1

项与 Astellas Pharma Technologies, Inc. 相关的临床试验

CTR20140097 / Active, not recruiting临床3期

多中心随机、双盲、平行组、安慰剂、活性对照的索利那新和米拉贝隆组合治疗膀胱过度活动症的研究

主要目的评估 2 种索利那新和米拉贝隆剂量组合相较于索利那新和米拉贝隆单独用药的有效性

开始日期2014-08-26

申办/合作机构

赛纽仕医药信息咨询（北京）有限公司

[+3]

100 项与 Astellas Pharma Technologies, Inc. 相关的临床结果

登录后查看更多信息

0 项与 Astellas Pharma Technologies, Inc. 相关的专利（医药）

登录后查看更多信息

1

项与 Astellas Pharma Technologies, Inc. 相关的文献（医药）

2013-07-07·Volume 1A, Symposia: Advances in Fluids Engineering Education; Advances in Numerical Modeling for Turbomachinery Flow Optimization; Applications in CFD; Bio-Inspired Fluid Mechanics; CFD Verification and Validation; Development and Applications of Immersed Boundary Methods; DNS, LES, and Hybrid RANS/LES Methods

Flow in a Human Renal Artery Network With a Saccular Aneurysm

作者: Judd, Eric ; Armstrong, Grant ; Lemley, Evan ; Espinoza, Wendy ; Peno, Samantha

Blood flow into the kidneys through the renal artery determines the systemic blood pressure which is regulated by the baroreceptors in the kidneys. When the baroreceptors sense decreases in local fluid pressure they stimulate the renin-angiotensin aldosterone (RAA) system, which increases systemic blood pressure by constricting blood vessels throughout the body.An aneurysm in the renal artery leads to high systemic blood pressure in most patients with this condition, but the mechanisms by which the pressure increase occurs are not well understood. One explanation of the pressure increase could be a drop in local fluid pressure near the aneurysm itself causing the RAA system to “correct” this low pressure by systemically increasing the blood pressure.The ongoing work reported here has focused on a model renal artery network with and without an aneurysm by simulating the flow with computational fluid dynamics (CFD) software. The fluid for the simulations was meant to mimic blood in terms of density and viscosity for shear stresses where Non-Newtonian flow effects should not be a concern. Flow into the renal artery was at a Reynolds number of almost 700, to mimic the flow rate in the renal artery. The simulations were performed to determine the difference in pressure between an inlet to the renal network and the exits from the network. These results indicate that the pressure difference through the network differed by less than 10 Pa comparing networks with and without saccular aneurysm. The pressure change that would trigger the RAA system is nearly 1000 Pa. So we conclude that the effect of changing the geometry with only a saccular aneurysm is not responsible for triggering the RAA system alone. Other effects that could lead to triggering of the RAA system are discussed as well as our initial construction of a system to perform validation experiments of our CFD results.

100 项与 Astellas Pharma Technologies, Inc. 相关的药物交易

登录后查看更多信息

100 项与 Astellas Pharma Technologies, Inc. 相关的转化医学

登录后查看更多信息